Open Nav
Program Overview

The BIO Patient & Health Advocacy Summit program is expanding! This year's lineup will feature discussions with thought leaders from the patient advocacy community and the biotechnology industry, as well as several new programs and workshops to make your Summit experience even more fulfilling.

Thursday, October 25

Best Practices for Engaging with Industry        
Location: Gallery Ballroom
10:30 AM - 12:00 PM

Patient advocate organizations and the biopharmaceutical industry share a commitment of improving the lives of patients, and often work together to better understand the patients served, raise awareness and understanding of a disease, and to advance patient-focused public policies. Many organizations, including BIO, have developed guiding principles of engagement for interactions with industry and stakeholder groups. This panel will explore the various best practice guidelines and will highlight some of the best practices learned in collaborations between the biopharmaceutical industry and patient advocacy organizations.

Lunch Roundtable Discussions
Location: Salon Rooms/ Gallery Ballroom
12:00 PM - 1:30 PM

An opportunity to network with peers from the healthcare community, the roundtable discussions will bring together Summit attendees from different stakeholder organizations, as well as the biotechnology industry, for robust discussions led by roundtable hosts.

View all Lunch Rountable Discussion Descriptions


Opening Remarks and Ensuring Patient Access and Affordability
Location: Gallery Ballroom

1:40 PM - 3:00 PM 

Opening Remarks by: Julie Gerberding, MD, MPH, Executive Vice President, Communications, Global Policy, and Population Health & Chief Patient Officer, Merck & Co., Inc.

In a world of continual innovation in biopharmaceuticals, how do we ensure patients have access to the medicines that work to meet their individual needs? This panel will cover the importance of understanding policies that may pose as barriers to access such as the acceleration of high patient cost-sharing and barriers to patient assistance programs, including co-pay accumulators, more adoption of utilization management tools like step-therapy, and the drive toward using cost-effectiveness analyses in coverage decisions. Panelists will provide insights into how patient advocate groups can respond as well as prepare themselves and their populations for these changes.

Networking Break
Location: Salon Foyer
3:00 PM - 3:15 PM

The Trump Administration's Blueprint: What's Next?
Location: Gallery Ballroom
3:15 PM - 4:30 PM 

Join us to hear from key members of the Administration as they discuss the Trump Administration’s efforts to lower drug prices and reduce patient out of pocket costs, as outlined in the American Patients First blueprint released earlier this year. 

Part 1: How to Engage with the Administration: Lessons from DC Insiders

Raissa Downs, Partner, Tarplin, Downs and Young LLC
Shannon Finley, Founding Partner, Capitol Counsel LLC
Dan Todd, Principal, Todd Strategy

Part 2: The Trump Administration's Blueprint

Closing Remarks 
Location: Gallery Ballroom
4:30 PM - 4:45 PM

Networking Reception
Location: Salon Rooms/ Salon Foyer
5:00 PM - 6:30 PM

Please stick around after the last session of the day for a networking reception with key stakeholders in the healthcare and patient advocacy communities.


Friday, October 26

Networking Breakfast
Location: Salon Rooms/ Salon Foyer
8:00 AM - 9:00 AM

Opioid Addiction: Changing the Paradigm for Treating Pain and Addiction
Location: Gallery Ballroom
9:00 AM - 10:15 AM

Understanding the biology underlying pain and addiction are critical to supporting the discovery of novel and safer treatments for both pain and addiction as well as for ensuring that patients receive the right treatment at the right time, with the right support, and without stigma.  This session will include a presentation followed by panel discussion regarding how we might best treat individuals suffering from pain while also doing our best to prevent addiction. The panel discussion will focus on three key areas, including the need to (1) better understand the biology of pain and addiction (2) ensure patients suffering from pain or addiction are able to receive the right support, without stigma, and (3) stimulate research and development of innovative treatments that effectively treat pain and opioid addiction and prevent abuse.

Background materials:
The State of Innovation in Highly Prevalent Chronic Diseases: Pain and Addiction Therapeutics
BIO’s Pain and Addiction Recommendations

Networking Break
Location: Salon Foyer
10:15 AM - 10:30 AM

FDA Update- Current Activities on Patient Experience Data
Location: Gallery Ballroom
10:30 - 11:45 AM

With the Prescription Drug User Fee Agreement V the Food and Drug Administration (FDA) worked along with other stakeholders including patient organizations and industry sponsors to further advance the systematic collection of patient experiences to inform drug development and review. In late 2017, the FDA held their first public meeting on “Patient-Focused Drug Development: Guidance 1 – Collecting Comprehensive and Representative Input” and during the summer of 2018, the Agency released the first draft guidance on the topic. This fall, the FDA held their second public meeting “Patient-Focused Drug Development Guidance: Methods to Identify What is Important to Patients and Select, Develop, or Modify Fit-for-Purpose Clinical Outcomes Assessments” to help inform additional patient-focused drug development guidance. This panel discussion will cover some of the key themes identified at the fall public meeting as well as how we can better support integration of patient experience data throughout the product lifecycle moving forward. 

Closing Remarks
Location: Gallery Ballroom

BIO One-on-One Partnering™
Location: Salon Rooms
12:00 PM - 3:30 PM

*Updated October 24, 2018. Subject to change.

Questions? Contact